Alogliptin fixed-dose combos move forward in Europe as filings accepted
This article was originally published in Scrip
Executive Summary
Takeda's delayed plans for the European commercialisation of alogliptin have taken another step forward with the formal acceptance for review by the European Medicines Agency of marketing authorisation applications for two fixed-dose combinations of the DPP-4 inhibitor.